## Neil Boudville

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5212335/publications.pdf

Version: 2024-02-01

75

all docs

74 2,122 26
papers citations h-index

75

docs citations

h-index g-index

75 2261
times ranked citing authors

43

#	Article	IF	CITATIONS
1	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. Peritoneal Dialysis International, 2022, 42, 279-287.	1.1	9
2	Variation in Peritoneal Dialysis–Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). American Journal of Kidney Diseases, 2022, 79, 45-55.e1.	2.1	30
3	Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation—a cohort study. Nephrology Dialysis Transplantation, 2022, 37, 760-769.	0.4	8
4	International peritoneal dialysis training practices and the risk of peritonitis. Nephrology Dialysis Transplantation, 2022, 37, 937-949.	0.4	15
5	Representativeness of the PDOPPS cohort compared to the Australian PD population. Peritoneal Dialysis International, 2022, 42, 403-414.	1.1	2
6	Incremental Versus Standard (Full-Dose) Peritoneal Dialysis. Kidney International Reports, 2022, 7, 165-176.	0.4	15
7	Peritoneal dialysis first policy in <scp>Hong Kong</scp> for 35 years: Global impact. Nephrology, 2022, 27, 787-794.	0.7	14
8	Equity and diversity in the nephrology workforce in Australia and New Zealand. Internal Medicine Journal, 2022, 52, 1900-1909.	0.5	4
9	MO716: A Different Pet Test: The Relationship between Pet Ownership and Peritonitis Risk in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	O
10	Optimizing Peritoneal Dialysis–Associated Peritonitis Prevention in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 154-161.	2.2	5
11	Impact of Perioperative Complications on Living Kidney Donor Health-Related Quality of Life and Mental Health: Results From a Prospective Cohort Study. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110374.	0.6	1
12	Home Versus Facility Dialysis and Mortality in Australia and New Zealand. American Journal of Kidney Diseases, 2021, 78, 826-836.e1.	2.1	10
13	Socioâ€economic disparity, access to care and patientâ€relevant outcomes after kidney allograft failure. Transplant International, 2021, 34, 2329-2340.	0.8	2
14	Living Kidney Donors' Financial Expenses and Mental Health. Transplantation, 2021, 105, 1356-1364.	0.5	4
15	KHAâ€CARI commentary on the KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Nephrology, 2020, 25, 96-98.	0.7	2
16	Use of patientâ€reported outcome measures and patientâ€reported experience measures in renal units in Australia and New Zealand: A crossâ€sectional survey study. Nephrology, 2020, 25, 14-21.	0.7	27
17	Peritoneal Dialysis–Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). American Journal of Kidney Diseases, 2020, 76, 42-53.	2.1	120
18	Reply to letter from A Karkar. Peritoneal Dialysis International, 2020, 40, 427-428.	1.1	0

#	Article	IF	CITATIONS
19	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	1.7	1
20	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	3.0	52
21	Effect of the proton-pumpÂlnhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Nephrology Dialysis Transplantation, 2020, 35, 1060-1070.	0.4	8
22	International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 244-253.	1.1	159
23	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. Peritoneal Dialysis International, 2020, 40, 47-56.	1.1	24
24	2005 Guidelines on targets for solute and fluid removal in adults being treated with chronic peritoneal dialysis: 2019 Update of the literature and revision of recommendations. Peritoneal Dialysis International, 2020, 40, 254-260.	1.1	14
25	Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry. Peritoneal Dialysis International, 2020, 40, 209-219.	1.1	4
26	"Can I go to Glasgow?―Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). Peritoneal Dialysis International, 2020, 40, 12-25.	1.1	5
27	Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective. Kidney360, 2020, 1, 829-833.	0.9	1
28	Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. Nephrology Dialysis Transplantation, 2019, 34, 2118-2126.	0.4	56
29	Relationship between pulse pressure and inflammation with left ventricular diastolic dysfunction in chronic kidney disease patients. Internal Medicine Journal, 2019, 49, 240-247.	0.5	2
30	Perioperative Complications During Living Donor Nephrectomy: Results From a Multicenter Cohort Study. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811985771.	0.6	17
31	An Intervention Design: Supporting Skills Development for Peritoneal Dialysis Trainers. Peritoneal Dialysis International, 2019, 39, 134-141.	1.1	18
32	The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients., 2019, 29, 377-385.		6
33	Physical activity for people with chronic kidney disease: an international survey of nephrologist practice patterns and research priorities. BMJ Open, 2019, 9, e032322.	0.8	26
34	Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. Nephrology Dialysis Transplantation, 2019, 34, 1035-1044.	0.4	12
35	Association between causes of peritoneal dialysis technique failure and all-cause mortality. Scientific Reports, 2018, 8, 3980.	1.6	32
36	Direct and indirect costs incurred by Australian living kidney donors. Nephrology, 2018, 23, 1145-1151.	0.7	8

#	Article	IF	Citations
37	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2018, 38, 257-265.	1.1	12
38	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. American Journal of Kidney Diseases, 2018, 72, 188-197.	2.1	85
39	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. American Journal of Kidney Diseases, 2018, 71, 814-821.	2.1	66
40	Teaching peritoneal dialysis in Australia: An opportunity for improvement. Nephrology, 2018, 23, 259-263.	0.7	15
41	Increased Inflammatory Response in Association with the Initiation of Hemodialysis Compared with Peritoneal Dialysis in a Prospective Study of End-Stage Kidney Disease Patients. Peritoneal Dialysis International, 2018, 38, 18-23.	1.1	15
42	FP468RISK PREDICTORS AND CAUSES OF TECHNIQUE FAILURE WITHIN THE FIRST YEAR OF PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2018, 33, i194-i194.	0.4	O
43	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	1.1	9
44	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open, 2018, 8, e018794.	0.8	60
45	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2017, 37, 619-626.	1.1	18
46	Impact of early conversion from cyclosporin to everolimus on left ventricular mass index: A randomized controlled trial. Clinical Transplantation, 2017, 31, e13043.	0.8	1
47	Risk-Factor Profile of Living Kidney Donors. Transplantation, 2016, 100, 1278-1283.	0.5	28
48	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. Peritoneal Dialysis International, 2016, 36, 547-554.	1.1	16
49	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 554-563.	2.1	51
50	Center-Specific Factors Associated with Peritonitis Riskâ€"A Multi-Center Registry Analysis. Peritoneal Dialysis International, 2016, 36, 509-518.	1.1	54
51	Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. Nephrology, 2016, 21, 535-546.	0.7	29
52	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Peritoneal Dialysis International, 2016, 36, 623-630.	1.1	71
53	The Cost of Organ Donation: Potential Living Kidney Donors' Perspectives: Table 1:. Health and Social Work, 2015, 40, 307-315.	0.5	5
54	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) Tj ETQqQ Nephrology: CJASN, 2015, 10, 1397-1407.	0 0 0 rgBT 2.2	/Overlock 10 <sup>-</sup> 50

Nephrology: CJASN, 2015, 10, 1397-1407.

#	Article	IF	Citations
55	Living kidney donation: outcomes, ethics, and uncertainty. Lancet, The, 2015, 385, 2003-2013.	6.3	174
56	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. Nephrology Dialysis Transplantation, 2015, 30, 1897-1904.	0.4	20
57	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	1.1	37
58	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrology Dialysis Transplantation, 2014, 29, 2277-2286.	0.4	40
59	End-stage renal disease in living kidney donors. Kidney International, 2014, 86, 20-22.	2.6	13
60	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1940-1947.	0.4	34
61	The Association between Peritoneal Dialysis Modality and Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1091-1097.	2.2	49
62	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1556-1563.	2.2	26
63	Comparison of the Diagnostic Accuracy of the <i> MSLN </i> Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum. Disease Markers, 2013, 35, 119-127.	0.6	31
64	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1398-1405.	3.0	198
65	Factors Associated with Chronic Kidney Disease Progression in Australian Nephrology Practices. Nephron Clinical Practice, 2012, 121, c36-c41.	2.3	5
66	Limited referral to nephrologists from a tertiary geriatric outpatient clinic despite a high prevalence of chronic kidney disease and anaemia. BMC Geriatrics, 2012, 12, 43.	1.1	3
67	The sensitivity and specificity of ultrasound estimation of central venous pressure using the internal jugular vein. Journal of Critical Care, 2012, 27, 315.e7-315.e11.	1.0	34
68	Mesothelin and kidney function—Analysis of relationship and implications for mesothelioma screening. Lung Cancer, 2011, 73, 320-324.	0.9	27
69	Relapsing and Recurrent Peritoneal Dialysis–Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2011, 58, 429-436.	2.1	63
70	Effect of FX Dialysers on Systemic Inflammation and Quality of Life in Chronic Haemodialysis Patients. Blood Purification, 2009, 27, 187-193.	0.9	8
71	The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. Nephrology Dialysis Transplantation, 2009, 24, 2926-2930.	0.4	26
72	Necrotising, proliferative glomerulonephritis due to monoclonal cryoglobulinaemia. Journal of Nephrology, 2006, 19, 372-4.	0.9	0

#	Article	lF	CITATIONS
73	Oral nutritional supplementation increases caloric and protein intake in peritoneal dialysis patients. American Journal of Kidney Diseases, 2003, 41, 658-663.	2.1	35
74	Evaluating data quality in the Australian and New Zealand dialysis and transplant registry using administrative hospital admission datasets and data-linkage. Health Information Management Journal, 0, , 183335832210977.	0.9	1